Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PDE5A | O76074 | 2/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23577767 | 1.00 | BACE1 (0.37) | BACE1ADORA2AADORA1ADORA2BABCG2 | |
| SCHEMBL23601533 | 0.87 | SMN1; SMN2 (0.40) | ABCG2MAPTPDE5A | |
| SCHEMBL23577125 | 0.87 | PDE5A (0.42) | ABCG2MAPTPDE5A | |
| SCHEMBL23576805 | 0.86 | ABCG2 (0.42) | BACE1ADORA2AADORA1ADORA2BABCG2 | |
| SCHEMBL29909532 | 0.86 | ABCG2 (0.42) | BACE1ADORA2AADORA1ADORA2BABCG2 | |
| SCHEMBL29909129 | 0.85 | LMNA (0.40) | MAPTNPC1RAB9A | |
| SCHEMBL23577361 | 0.85 | LMNA (0.40) | MAPTNPC1RAB9A | |
| SCHEMBL29909329 | 0.85 | ABCG2 (0.47) | ABCG2PDE5A | |
| SCHEMBL23577176 | 0.85 | ABCG2 (0.47) | ABCG2PDE5A | |
| SCHEMBL23576963 | 0.84 | ABCG2 (0.42) | ABCG2PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| EP-4081305-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | Carna Biosciences, Inc. (JP) | 2022-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | DGKG, DGKB, DGKK | BACE1 4325/4885ADORA2A 1180/4885ADORA1 2763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.